Acorda Therapeutics (ACOR) Tops Q3 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aegis Affirms Acorda (ACOR) at 'Buy' Following Q3 Results Update; Sees Ampyra Continuing to Improve
October 23, 2015 10:39 AM EDTAegis Capital affirms its Buy rating and $40 price target on Acorda Therapeutics, Inc. (Nasdaq: ACOR) following Q3 results and IPR update issued Thursday.
On ACOR's results, analyst Robert LeBoyer commented: Acorda reported Ampyra sales of $117 million for 3Q15, beating our estimate of... More
